We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Exiqon Licenses Locked Nucleic Acids for siRNA to Applied Biosystems

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exiqon Licenses Locked Nucleic Acids for siRNA to Applied Biosystems"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Exiqon A/S has announces that it has granted a license to Applied Biosystems to use Exiqon’s proprietary Locked Nucleic Acids (LNA™) in siRNA. The details of the financial terms of the license agreement are not disclosed.

The license agreement with Applied Biosystems fulfills a strategic goal Exiqon had originally set for 2008 to enter in to an agreement with a major tool provider for a license to LNA™.

The proprietary LNA technology offers many more possibilities for developing competitive products than can be pursued by Exiqon. It is therefore an inherent part of Exiqon’s strategy to capitalize on its proprietary LNA technology within a market that Exiqon does not plan to pursue itself through license agreements and partnerships with third parties. One such market segment is siRNA.

Short interfering RNA (or siRNA) molecules are short, gene-specific synthetic molecules, which when introduced into cells or animals, specifically down regulate the genes to which they are targeted. siRNAs comprise a very powerful technique to silence gene expression in cells which allows biomedical researchers to study the molecular effects of modulating expression at the level of individual genes.